The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Pulmonary Drugs Market By 2030 Starting From Its 2026 Size?
The pulmonary drugs market size has experienced significant growth in recent years. It is anticipated to expand from $56.98 billion in 2025 to $60.07 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.4%. This historical expansion can be attributed to factors such as the increasing prevalence of asthma, a rise in COPD incidence, growing urban air pollution, the expansion of inhalation drug delivery systems, and improved diagnosis of respiratory diseases.
The pulmonary drugs market size is anticipated to experience substantial growth in the upcoming years, with projections indicating it will expand to $74.14 billion by 2030, achieving a compound annual growth rate (CAGR) of 5.4%. This expansion during the forecast period is primarily attributed to factors such as an increasing aging population, the proliferation of biologic pulmonary drugs, the adoption of precision respiratory medicine, a rise in smoking-related disorders, and improved access to inhaled therapies. Significant trends expected during this period encompass a growing uptake of targeted respiratory treatments, the development of combination inhalation therapies, an increased focus on long-term disease management, the widening availability of biologic-based pulmonary drugs, and a shift towards personalized respiratory care.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp
What Major Growth Drivers Are Shaping The Outlook Of The Pulmonary Drugs Market?
The expanding occurrence of respiratory illnesses is projected to fuel the expansion of the pulmonary drugs market in the future. These disorders are defined as health conditions impacting the lungs and airways, hindering regular respiration and gas exchange. The rise in respiratory disorders is linked to the increasing rate of smoking, which results in lung damage and long-term illnesses. Pulmonary medications are vital for treating respiratory conditions, as they enhance lung function, decrease inflammation, and alleviate blockages in the airways, facilitating improved breathing. For example, data from May 2025 by the US-based government agency, the Centers for Disease Control and Prevention, indicated that in 2023, the age-adjusted prevalence of COPD among adults 18+ stood at 3.8%, with women experiencing a higher rate (4.1%) compared to men (3.4%). The prevalence of COPD also significantly escalated with age, climbing from 0.4% in individuals aged 18–24 to 10.5% in those 75 and older. Consequently, the growing incidence of respiratory ailments is serving as a key driver for the expansion of the pulmonary drugs market.
Which Segment Categories Define The Pulmonary Drugs Market?
The pulmonary drugs market covered in this report is segmented –
1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes
2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications
3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies
Subsegments:
1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide
2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol
3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine
4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues
5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol
6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes
What Major Market Trends Are Driving Changes In The Pulmonary Drugs Market?
Leading firms within the pulmonary drugs market are prioritizing novel therapeutic approaches, specifically dual PDE3 and PDE4 inhibition administered by inhalation, aiming to integrate both bronchodilator and non-steroidal anti-inflammatory actions into one compound for the ongoing management of chronic obstructive pulmonary disease (COPD). This dual PDE3 and PDE4 inhibition facilitates concurrent relaxation of the airways and a decrease in lung inflammation, thus more effectively managing persistent COPD symptoms compared to conventional treatments and streamlining delivery by eliminating the need for intricate inhalation methods. As an example, in June 2024, Verona Pharma plc, a biopharmaceutical company headquartered in the UK, obtained U.S. FDA approval for Ohtuvayre (ensifentrine), notable as the first inhaled therapy demonstrating this dual-mechanism approach in over 20 years. Administered through a standard jet nebulizer, Ohtuvayre delivers both bronchodilator and anti-inflammatory advantages in one dose, having demonstrated clinical effectiveness as a standalone treatment and when combined with other ongoing therapies during the Phase 3 ENHANCE trials, with anticipated availability via specialty pharmacies in the U.S. by the third quarter of 2024.
Who Are The Top Companies Competing In The Pulmonary Drugs Market?
Major companies operating in the pulmonary drugs market are AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.
Read the full pulmonary drugs market report here:
https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report
Which Regions Are Projected To Dominate The Pulmonary Drugs Market In The Coming Years?
North America was the largest region in the pulmonary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Pulmonary Drugs Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp
Browse Through More Reports Similar to the Global Pulmonary Drugs Market 2026, By The Business Research Company
Respiratory Disease Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report
Pulmonary Drug Delivery Devices Market Report 2026
Lung Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model